Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brigitte M. Pützer has a total of 183 co-authors. Here are the top co-authors by number of shared publications:

  • Alf Spitschak

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Rostock, Germany

    12 shared publications
  • David Engelmann

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057 Rostock, Germany

    10 shared publications
  • Vijay Alla

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Rostock, Germany

    9 shared publications
  • Ottmar Herchenröder

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany

    8 shared publications
  • Stephan Marquardt

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Rostock, Germany

    7 shared publications
  • Katharina Fürst

    Institute of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, 18057, Rostock, Germany

    6 shared publications

Latest Publications

  • Open Access

    Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape

    by Alf Spitschak, Rosaely Casalegno Garduño, Brigitte M. Pützer

    Cancer biomarker discovery has traditionally focused on individual molecular features; however, tumor behavior and therapeutic response are governed by integrated transcriptional and epigenetic programs that shape immune and microenvironmental states. Deciphering the determinants of metastatic evolution and the complexity of cancer ecosystems is imperative for designing novel preventive and targeted therapies. Tumor complexity, driven by intrinsic cellular heterogeneity and the dynamic plasticity of cancer cells in response to microenvironmental cues, complicates therapeutic strategies based solely on defined molecular or genetic traits. Consequently, there is an urgent need for reliable predictive biomarkers that reflect cancer vulnerabilities, indicate disease progression, or predict patient-specific therapeutic responses to enable truly individualized treatment strategies. Current biomarkers encompass genetic and epigenetic alterations, non-coding RNAs, epithelial-mesenchymal transition-, stemness-, and metastasis-associated transcription factors, as well as cellular components of the tumor microenvironment, including immune cell subsets and cancer-associated fibroblasts. In immuno-oncology, additional biomarkers such as tumor mutational burden, mismatch repair deficiency/microsatellite instability-high status, and PD-L1 expression are widely used for patient stratification. Importantly, the reversible nature of epigenetic modifications, aberrant transcription factor activity, and cell-intrinsic signaling alterations, together with dynamic interactions within the tumor microenvironment, profoundly influence cancer behavior and treatment outcomes. This review summarizes recent advances in cancer and immune-related biomarker research. It outlines a regulatory, systems-level framework that integrates tumor-intrinsic gene control programs with multi-omic, cellular, spatial, and AI-enabled biomarkers. This framework aims to capture tumor plasticity more effectively and advance precision oncology.


  • Open Access

    Integrative Multimodal Profiling of TAp73 and DNp73 Reveals Isoform-Specific Transcriptomic Coregulator Landscapes in Cancer Programs

    by Steffen Möller, Alf Spitschak, Nico Murr, Brigitte M. Pützer

    (1) Background: The transcription factor p73 exists in multiple isoforms with divergent functions in cancer. While DNp73 promotes stemness, epithelial–mesenchymal transition (EMT), and metastasis, the tumor-suppressive isoform TAp73 can also switch to promoting cancer progression. How isoforms sharing the same DNA-binding domain produce divergent outcomes remains unclear. (2) Methods: Here, we performed CUT&RUN in combination with JASPAR, transcriptomics, proteomics, patient survival and gene expression data to map genome-wide and promoter-associated DNA-binding and coregulatory transcription factor (coTF) profiles of TAp73α and DNp73β in melanoma cells. (3) Results: Systematic screening for motif enrichment in cancer hallmark gene sets revealed TAp73- and DNp73-specific coTF repertoires with distinct functions. We identified a coregulator signature for EMT genes enriched for both isoforms that has tumor context-dependent effects on survival and correlates with unfavorable patient prognosis. Of these EMT-associated coTFs, PATZ1 was validated as a novel direct interactor of DNp73β. (4) Conclusions: Our results provide a comprehensive reference map of p73 isoform-specific binding and coregulator recruitment and establish a workflow to model their influence on cancer reprogramming with implications for AI-based individualized therapy.

  • Open Access

    TAp73α drives cancer metastasis via PPI-mediated derepression of the neuronal HDAC2/REST-GABBR2 axis

    by Nico Murr, Christin Richter, Shailendra K. Gupta, Elke Hammer, Nares Trakooljul, Anja Stoll, Steffen Möller, Lukas E. Neumann, Brigitte M. Pützer, Alf Spitschak


  • Open Access

    CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy

    by Rosaely Casalegno Garduño, Alf Spitschak, Tim Pannek, Brigitte M. Pützer

    The advent of immune checkpoint blockade (ICB) has transformed cancer immunotherapy, enabling remarkable long-term outcomes and improved survival, particularly with ICB combination treatments. However, clinical benefits remain confined to a subset of patients, and life-threatening immune-related adverse effects pose a significant challenge. This limited efficacy is attributed to cancer heterogeneity, which is mediated by ligand–receptor interactions, exosomes, secreted factors, and key transcription factors. Oncogenic regulators like E2F1 and MYC drive metastatic tumor environments and intertwine with immunoregulatory pathways, impairing T cell function and reducing immunotherapy effectiveness. To address these challenges, FDA-approved biomarkers, such as tumor mutational burden (TMB) and programmed cell death-ligand 1 (PD-L1) expression, help to identify patients most likely to benefit from ICB. Yet, current biomarkers have limitations, making treatment decisions difficult. Recently, T cells—the primary target of ICB—have emerged as promising biomarkers. This review explores the relationship between cancer drivers and immune response, and emphasizes the role of CD8+ T cells in predicting and monitoring ICB efficacy. Tumor-infiltrating CD8+ T cells correlate with positive clinical outcomes in many cancers, yet obtaining tumor tissue remains complex, limiting its practical use. Conversely, circulating T cell subsets are more accessible and have shown promise as predictive biomarkers. Specifically, memory and progenitor exhausted T cells are associated with favorable immunotherapy responses, while terminally exhausted T cells negatively correlate with ICB efficacy. Ultimately, combining biomarkers enhances predictive accuracy, as demonstrated by integrating TMB/PD-L1 expression with CD8+ T cell frequency. Computational models incorporating cancer and immune signatures could further refine patient stratification, advancing personalized immunotherapy.


  • Open Access

    E2F1-induced autocrine IL-6 inflammatory loop mediates cancer-immune crosstalk that predicts T cell phenotype switching and therapeutic responsiveness

    by Alf Spitschak, Prabir Dhar, Krishna P. Singh, Rosaely Casalegno Garduño, Shailendra K. Gupta, Julio Vera, Luca Musella, Nico Murr, Anja Stoll, Brigitte M. Pützer

    Melanoma is a metastatic, drug-refractory cancer with the ability to evade immunosurveillance. Cancer immune evasion involves interaction between tumor intrinsic properties and the microenvironment. The transcription factor E2F1 is a key driver of tumor evolution and metastasis. To explore E2F1’s role in immune regulation in presence of aggressive melanoma cells, we established a coculture system and utilized transcriptome and cytokine arrays combined with bioinformatics and structural modeling. We identified an E2F1-dependent gene regulatory network with IL6 as a central hub. E2F1-induced IL-6 secretion unleashes an autocrine inflammatory feedback loop driving invasiveness and epithelial-to-mesenchymal transition. IL-6-activated STAT3 physically interacts with E2F1 and cooperatively enhances IL-6 expression by binding to an E2F1-STAT3-responsive promoter element. The E2F1-STAT3/IL-6 axis strongly modulates the immune niche and generates a crosstalk with CD4+ cells resulting in transcriptional changes of immunoregulatory genes in melanoma and immune cells that is indicative of an inflammatory and immunosuppressive environment. Clinical data from TCGA demonstrated that elevated E2F1, STAT3, and IL-6 correlate with infiltration of Th2, while simultaneously blocking Th1 in primary and metastatic melanomas. Strikingly, E2F1 depletion reduces the secretion of typical type-2 cytokines thereby launching a Th2-to-Th1 phenotype shift towards an antitumor immune response. The impact of activated E2F1-STAT3/IL-6 axis on melanoma-immune cell communication and its prognostic/therapeutic value was validated by mathematical modeling. This study addresses important molecular aspects of the tumor-associated microenvironment in modulating immune responses, and will contribute significantly to the improvement of future cancer therapies.


  • Open Access

    Novel Viral Vectors for Gene Therapy

    by Ottmar Herchenröder, Brigitte M. Pützer

    Viral vectors are gene transfer tools assembled from the backbones of naturally occurring viruses


  • Open Access

    Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease

    by Alf Spitschak, Shailendra Gupta, Krishna P. Singh, Stella Logotheti, Brigitte M. Pützer

    Cancer cells have a remarkable ability to evade recognition and destruction by the immune system. At the same time, cancer has been associated with chronic inflammation, while certain autoimmune diseases predispose to the development of neoplasia. Although cancer immunotherapy has revolutionized antitumor treatment, immune-related toxicities and adverse events detract from the clinical utility of even the most advanced drugs, especially in patients with both, metastatic cancer and pre-existing autoimmune diseases. Here, the combination of multi-omics, data-driven computational approaches with the application of network concepts enables in-depth analyses of the dynamic links between cancer, autoimmune diseases, and drugs. In this review, we focus on molecular and epigenetic metastasis-related processes within cancer cells and the immune microenvironment. With melanoma as a model, we uncover vulnerabilities for drug development to control cancer progression and immune responses. Thereby, drug repurposing allows taking advantage of existing safety profiles and established pharmacokinetic properties of approved agents. These procedures promise faster access and optimal management for cancer treatment. Together, these approaches provide new disease-based and data-driven opportunities for the prediction and application of targeted and clinically used drugs at the interface of immune-mediated diseases and cancer towards next-generation immunotherapies.


  • Open Access

    Novel integrated workflow allows production and in-depth quality assessment of multifactorial reprogrammed skeletal muscle cells from human stem cells

    by Dinis Faustino, Heinrich Brinkmeier, Stella Logotheti, Anika Jonitz-Heincke, Hande Yilmaz, Isil Takan, Kirsten Peters, Rainer Bader, Hermann Lang, Athanasia Pavlopoulou, et al.

    Skeletal muscle tissue engineering aims at generating biological substitutes that restore, maintain or improve normal muscle function; however, the quality of cells produced by current protocols remains insufficient. Here, we developed a multifactor-based protocol that combines adenovector (AdV)-mediated MYOD expression, small molecule inhibitor and growth factor treatment, and electrical pulse stimulation (EPS) to efficiently reprogram different types of human-derived multipotent stem cells into physiologically functional skeletal muscle cells (SMCs). The protocol was complemented through a novel in silico workflow that allows for in-depth estimation and potentially optimization of the quality of generated muscle tissue, based on the transcriptomes of transdifferentiated cells. We additionally patch-clamped phenotypic SMCs to associate their bioelectrical characteristics with their transcriptome reprogramming. Overall, we set up a comprehensive and dynamic approach at the nexus of viral vector-based technology, bioinformatics, and electrophysiology that facilitates production of high-quality skeletal muscle cells and can guide iterative cycles to improve myo-differentiation protocols.


  • Open Access

    Editorial: Multidisciplinary Approaches in Exploring Cancer Heterogeneity, TME and Therapy Resistance: Perspectives for Systems Medicine

    by Brigitte M. Pützer, Kanaga Sabapathy

    Editorial: Multidisciplinary Approaches in Exploring Cancer Heterogeneity, TME and Therapy Resistance: Perspectives for Systems Medicine


  • Open Access

    Mechanisms of Functional Pleiotropy of p73 in Cancer and Beyond

    by Stella Logotheti, Christin Richter, Nico Murr, Alf Spitschak, Stephan Marquardt, Brigitte M. Pützer

    The transcription factor p73 is a structural and functional homolog of TP53, the most famous and frequently mutated tumor-suppressor gene. The TP73 gene can synthesize an overwhelming number of isoforms via splicing events in 5′ and 3′ ends and alternative promoter usage. Although it originally came into the spotlight due to the potential of several of these isoforms to mimic p53 functions, it is now clear that TP73 has its own unique identity as a master regulator of multifaceted processes in embryonic development, tissue homeostasis, and cancer. This remarkable functional pleiotropy is supported by a high degree of mechanistic heterogeneity, which extends far-beyond the typical mode of action by transactivation and largely relies on the ability of p73 isoforms to form protein–protein interactions (PPIs) with a variety of nuclear and cytoplasmic proteins. Importantly, each p73 isoform carries a unique combination of functional domains and residues that facilitates the establishment of PPIs in a highly selective manner. Herein, we summarize the expanding functional repertoire of TP73 in physiological and oncogenic processes. We emphasize how TP73’s ability to control neurodevelopment and neurodifferentiation is co-opted in cancer cells toward neoneurogenesis, an emerging cancer hallmark, whereby tumors promote their own innervation. By further exploring the canonical and non-canonical mechanistic patterns of p73, we apprehend its functional diversity as the result of a sophisticated and coordinated interplay of: (a) the type of p73 isoforms (b) the presence of p73 interaction partners in the cell milieu, and (c) the architecture of target gene promoters. We suppose that dysregulation of one or more of these parameters in tumors may lead to cancer initiation and progression by reactivating p73 isoforms and/or p73-regulated differentiation programs thereof in a spatiotemporally inappropriate manner. A thorough understanding of the mechanisms supporting p73 functional diversity is of paramount importance for the efficient and precise p73 targeting not only in cancer, but also in other pathological conditions where TP73 dysregulation is causally involved.